LumiraDx Ltd - SIC # 3826 - LABORATORY ANALYTICAL INSTRUMENTS

Ticker Exchange SIC # Website Latest Ticker
LMDX Nasdaq 3826 https://www.lumiradx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for LumiraDx Ltd

Q4 2022 LumiraDx Ltd Earnings Call - Mar 22nd, 2023 3:40 am
LumiraDx Limited (LMDX) Reports Q4 Loss, Tops Revenue Estimates - Mar 21st, 2023 12:45 pm
LumiraDx Reports Fourth Quarter and Full Year 2022 Results - Mar 21st, 2023 11:26 am
LumiraDx to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Quarterly Conference Call on March 21 - Mar 14th, 2023 12:03 pm
LumiraDx to Present at Raymond James Institutional Investors Conference - Mar 3rd, 2023 2:00 pm
One LumiraDx Limited (NASDAQ:LMDX) insider upped their stake by 150% in the previous year - Feb 23rd, 2023 1:14 pm
LumiraDx Regains Compliance with Nasdaq Continued Listing Requirements - Feb 17th, 2023 9:15 pm
LumiraDx Receives FDA Emergency Use Authorization and UK CTDA Approval for its Fast Lab Solutions Multiplex COVID and Influenza Molecular Assay - Feb 6th, 2023 1:00 pm
LumiraDx Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK - Jan 31st, 2023 9:30 pm
LumiraDx Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency - Jan 31st, 2023 9:15 pm
12 Best One Dollar Stocks to Buy According To Hedge Funds - Jan 27th, 2023 2:32 pm
LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test - Dec 14th, 2022 8:19 am
Point of Care (POC) Survey Reveals Majority of U.K. Clinicians Endorse Climate Benefits of POC Through Reduction of Carbon Emissions and Anticipate Future Growth of POC Testing to Come from Community Settings - Dec 8th, 2022 8:01 am
Latest Clinicians’ U.S. Survey Identifies Point of Care Testing (POCT) as a Way to Address Healthcare Bandwidth Pressures and Anticipates Future Growth of POCT in Community Testing Centers - Dec 8th, 2022 8:01 am
What You Need To Know About The LumiraDx Limited (NASDAQ:LMDX) Analyst Downgrade Today - Nov 16th, 2022 11:02 am
LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test - Nov 14th, 2022 3:24 pm
LumiraDx Third Quarter 2022 Earnings: Revenues Beat Expectations - Nov 11th, 2022 10:35 am
LumiraDx Limited (LMDX) Reports Q3 Loss, Tops Revenue Estimates - Nov 9th, 2022 1:25 pm
LumiraDx Reports Third Quarter 2022 Results - Nov 9th, 2022 12:00 pm
LumiraDx to Announce Third Quarter Financial Results and Host Quarterly Conference Call on November 9 - Nov 2nd, 2022 11:23 am